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Clinical
Outcome
XIENCE PRIME Observed Rate
CSR (N401)
XIENCE PRIME Observed Rate
LLR (N104)
One Year Two Years One Year Two Years
TLF (per WHO) 4.5% (18/399) 6.4% (25/392) 7.7% (8/104) 9.6% (10/104)
TLF (per ARC) 6.5% (26/399) 8.4% (33/392) 12.5% (13/104) 14.4% (15/104)
Cardiac Death 0.3% (1/399) 0.5% (2/392) 0.0% (0/104) 0.0% (0/104)
All MI (per
WHO)
1.8% (7/399) 2.0% (8/392) 4.8% (5/104) 5.8% (6/104)
All MI (per
ARC)
4.5% (18/399) 5.9% (23/392) 10.6% (11/104) 11.5% (12/104)
TV-MI (per
WHO)
1.8% (7/399) 1.8% (7/392) 4.8% (5/104) 4.8% (5/104)
TV-MI (per
ARC)
4.0% (16/399) 4.6% (18/392) 10.6% (11/104) 10.6% (11/104)
CI-TLR 2.5% (10/399) 4.1% (16/392) 2.9% (3/104) 4.8% (5/104)
ARC-Defined
Stent
Thrombosis
(Definite/
Probable)
0.5% (2/399) 0.5% (2/386) 0.0% (0/104) 0.0% (0/100)
Notes: -
N is the total number of subjects.
- Population for SPIRIT PRIME consists of those subjects who were treated with at
least one XIENCE PRIME stent and had cardiac enzyme data between 8 hours post
index procedure and hospital discharge.
- TLF includes cardiac death, target vessel MI or clinically indicated TLR.
- Time frame includes follow-up window (1-year: 365  28 days, 2-year: 730  28
days).
- TLF from hierarchical counts; other outcomes from non-hierarchical counts.
- WHO: World Health Organization.
- ARC: Academic Research Consortium.
Conclusions: The SPIRIT PRIME study demonstrated sustained 2-year safety and
efficacy of the new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates
in both core size and long lesion cohorts and no new ARC definite/probable ST events in
either arm.
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China
Background: This study was sought to investigate the impact of complete revascular-
ization (CR) vs. incomplete revascularization (IR) on long-term outcomes in patients with
multivessel coronary disease (MVD) in current practice of percutaneous coronary
intervention (PCI).
Methods: Between April 2004 and November 2010, 7376 consecutive patients with
MVD underwent PCI at our center. Patients who underwent prior CABG and those who
had an acute myocardial infarction (MI) within 24 hours before revascularization or
presented with cardiogenic shock were excluded.
Results: Among 7065 patients with MVD undergoing PCI treatment, angiographic CR
was performed in 1188 patients (16.8%), and proximal CR in 2053 patients (29.1%). The
study found that either angiographic or proximal IR were associated with significantly
higher estimated 3-year rate of cardiac death (2.55% vs. 1.13%, log-rank p0.016; and
2.70% vs. 1.43%, log-rank p0.024; respectively). After adjustment for differences in
baseline characteristics between IR and CR patients, angiographic IR was associated with
a significantly higher rate of cardiac death (adjusted hazards ratio [HR]: 2.56, 95%
confidence interval [CI]: 1.03 to 6.41) while proximal IR was associated with a
numerically higher rate of cardiac death (adjusted HR: 1.72, 95% CI: 0.93 to 3.17). For
the subgroup of 2-vessel IR with total occlusion, either angiographic or proximal IR
patients had significantly higher rate of cardiac death (adjusted HR: 4.25, 95% CI: 1.50 to
12.09; and adjusted HR: 3.02, 95% CI: 1.40 to 6.52; respectively).
Conclusions: Compared with IR, patients with CR had better clinical outcomes,
especially when only single vessels were treated, supporting CR as first choice for patients
with MVD.
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Background: PCI stent inflation pressure correlates to angiographic lumen improvement
and stent expansion but the relation to outcome is not clarified. Using comprehensive
registry data our aim was to evaluate how stent inflation pressure influences restenosis and
stent thrombosis following PCI.
Methods: We evaluated all consecutive coronary stent implantations in Sweden from
January 1, 2008, to October 26, 2011 using data from the Swedish Coronary Angiography
and Angioplasty Registry (SCAAR). We used logistic regression and Cox proportional
hazard modeling to estimate risk of outcomes with different balloon pressures.
Results: In total, 93 697 stents were eligible for analysis and divided into five different
pressure interval groups: 15 atm, 16-17 atm, 18-19 atm, 20-21 atm and 22 atm. The
risks of stent thrombosis (Fig.) and restenosis were significantly higher in the 15 atm,
18-19 atm and 22 atm groups (but not in the 16-17 atm group) compared to the 20-21
atm group. Post-dilatation was associated with a higher restenosis risk ratio (RR) of 1.22
(95% confidence interval (CI) 1.14-1.32, P0.001) but stent thrombosis did not differ
statistically between procedures with or without post-dilatation.
Conclusions: Our retrospective study identified a possible optimal stent inflation pressure
of 20-21 atm during PCI which was associated with a lower risk of stent thrombosis and
restenosis. Post-dilatation might increase restenosis risk.
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Background: Long coronary lesions are a risk factor for increased restenosis and event
rates following coronary stenting. The PLATINUM Long Lesion study evaluates the
PROMUS Element platinum chromium everolimus-eluting stent (Boston Scientific,
Natick, MA) for the treatment of long coronary lesions. Two year results have not yet
been reported.
Methods: The prospective, single-arm PLATINUM Long Lesion (LL) study enrolled
102 patients at 30 clinical sites. Patients had angina pectoris or documented silent
ischemia. One de novo target lesion24 to34mm long with reference diameter2.50
to 4.25mm could be treated with a 32 or 38mm stent. A lesion in a different epicardial
vessel could be treated with a non-study treatment before the target lesion. Exclusion
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